Relationships among oncostatin M, insulin resistance, and chronic inflammation: a pilot study

Akarsu, Murat; Hurşitoğlu, Mehmet; Toprak, Zeki; Yoldemir, Şengül Aydin; Altun, Özgür; Toprak, Ilkim Deniz; Özcan, Mustafa; Yürüyen, Gülden; Uğurlukişi, Bilal; Erdem, Mahmut Genco; Kirna, Kerem; Demir, Pinar; Çapar, Gazi; Arman, Yücel; Tükek, Tufan.
Arch. endocrinol. metab. (Online) ; 64(1): 38-44, Jan.-Feb. 2020. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1088772

Documentos relacionados

  1. Relationships among oncostatin M, insulin resistance, and chronic inflammation: a pilot study.
  2. Mobilizing serum factors and immune cells through exercise to counteract age-related changes in cancer risk.
  3. Relationship between serum oncostatin M levels and degree of coronary stenosis in patients with coronary artery disease.
  4. Plasma Oncostatin M, TNF-α, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop.
  5. Increased level of LIGHT/TNFSF14 is associated with survival in aneurysmal subarachnoid hemorrhage.
  6. Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery.
  7. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay.
  8. Macrophage colony stimulating factor and monocyte chemoattractant protein 2 are elevated in intrinsic asthmatics.
  9. Oncostatin M Is a Prognostic Biomarker and Inflammatory Mediator for Sepsis.
  10. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.